Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00480324
Other study ID # 107625
Secondary ID 2015-001543-36
Status Completed
Phase Phase 3
First received
Last updated
Start date June 19, 2007
Est. completion date November 21, 2009

Study information

Verified date December 2019
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is undertaken to provide the regulatory authorities in Japan with immunogenicity, efficacy, safety and reactogenicity data of GSK Biologicals' Human Rotavirus [HRV] vaccine, given as a 2-dose primary vaccination, in healthy Japanese infants aged approximately 2 months at the time of the first dose and previously uninfected with HRV. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Description:

Combined diphtheria and tetanus toxoids and acellular pertussis (DTPa) and Hepatitis B (HBV) vaccines are allowed to be co-administered along with Rotarix vaccine/Placebo.


Recruitment information / eligibility

Status Completed
Enrollment 765
Est. completion date November 21, 2009
Est. primary completion date March 31, 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks to 14 Weeks
Eligibility Inclusion Criteria:

- Healthy male or female infant between, and including, 6 and 14 weeks (42-104 days) of age at the time of the first vaccination.

- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study

- Healthy subjects as established by medical history and clinical examination before entering into the study.

- Written informed consent obtained from the parent or guardian of the subject.

- Born between a gestation period of 36 and 42 weeks inclusive.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use during the study period.

- History of use of experimental rotavirus vaccine.

- Chronic administration of immunosuppressants or other immune-modifying drugs since birth.

- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).

- Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for intussusception.

- Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition determined by the investigator.

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

- Previous confirmed occurrence of RV GE.

- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).

- A family history of congenital or hereditary immunodeficiency.

- Acute disease at the time of enrolment.

- Gastroenteritis within 7 days preceding the study vaccine administration.

- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Study Design


Intervention

Biological:
Rotarix
Two-dose oral vaccination.
Placebo
Two-dose oral administration.

Locations

Country Name City State
Japan GSK Investigational Site Aichi
Japan GSK Investigational Site Chiba
Japan GSK Investigational Site Fukuoka
Japan GSK Investigational Site Hiroshima
Japan GSK Investigational Site Hiroshima
Japan GSK Investigational Site Hiroshima
Japan GSK Investigational Site Hiroshima
Japan GSK Investigational Site Hiroshima
Japan GSK Investigational Site Hokkaido
Japan GSK Investigational Site Hokkaido
Japan GSK Investigational Site Kagawa
Japan GSK Investigational Site Kanagawa
Japan GSK Investigational Site Miyagi
Japan GSK Investigational Site Miyagi
Japan GSK Investigational Site Nagano
Japan GSK Investigational Site Nagasaki
Japan GSK Investigational Site Niigata
Japan GSK Investigational Site Okayama
Japan GSK Investigational Site Okayama
Japan GSK Investigational Site Osaka

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Japan, 

References & Publications (4)

Buyse H, Vinals C, Karkada N, Han HH. The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicity. Hum Vaccin Immunother. 2014;10(1):19-24. doi: 10.4161/hv.26476. Epub 2013 Oct 8. — View Citation

Kawamura N et al. Efficacy of Human Rotavirus (G1P[8] strain) Vaccine (HRV) RIX4414 in Japanese Infants during the Two-year Efficacy Follow-up Period. Abstract presented at the 114th Annual Meeting of Japan Pediatric Society (JPS). Tokyo, Japan, 12-14 August 2011.

Kawamura N et al. Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point. Abstract presented at the 28th meeting of European Society for Paediatric Infectious Diseases (ESPID). Nice, France, 4-8 May 2010.

Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran PV, Han HH. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine. 2011 Aug 26;29(37):6335-41. doi: 10.1016/j.vaccine.2011.05.017. Epub 2011 Jun 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode. From 2 weeks after Dose 2 up to 2 years of age
Secondary Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system). From 2 weeks after Dose 2 up to 2 years of age
Secondary Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe RV GE was defined as an episode of rotavirus gastroenteritis with score = 11 on a 20-point scoring system (Vesikari scoring system).
From 2 weeks after Dose 2 up to 2 years of age
Secondary Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score = 11 on a 20-point scoring system (Vesikari scoring system).
From 2 weeks after Dose 2 up to 2 years of age
Secondary Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode. From 2 weeks after Dose 2 up to 2 years of age
Secondary Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score = 11 on a 20-point scoring system (Vesikari scoring system).
From Dose 1 up to 2 years of age
Secondary Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL). 2 months after Dose 2
Secondary Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration = 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative. 2 months after Dose 2
Secondary Number of Subjects Reporting Solicited Symptoms Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting. During the 8-day follow-up period after each dose
Secondary Number of Subjects Reporting Unsolicited Adverse Events (AEs) Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. During the 31-day follow-up period after each dose
Secondary Number of Subjects Reporting Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Up to 2 years of age
See also
  Status Clinical Trial Phase
Completed NCT01435967 - Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™ N/A
Completed NCT00345956 - To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam) Phase 3
Completed NCT00370318 - Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines Phase 3
Completed NCT00140686 - To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines Phase 3
Completed NCT00383903 - Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa Phase 2
Completed NCT00750893 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
Completed NCT00533507 - Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age Phase 3
Completed NCT00363545 - To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) Phase 3
Completed NCT02914184 - Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks Phase 3
Completed NCT00489567 - Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden N/A
Completed NCT01733862 - Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
Completed NCT00779779 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
Completed NCT00382772 - A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine). Phase 3
Completed NCT00729001 - Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants. Phase 2
Completed NCT00353366 - To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
Completed NCT01198769 - Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth. Phase 4
Completed NCT00385320 - Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months Phase 2
Completed NCT00432380 - A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants. Phase 2
Completed NCT01563159 - Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011 N/A
Completed NCT01339221 - Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium N/A